PhenoAgeAccel from routine blood tests in older cancer patients
In 173 patients at a geriatric oncology clinic, a biological-age measure from routine blood tests (PhenoAge) averaged higher than chronological age, and its residual above expected age was reported as a greater risk predictor than chronological age. [1]
Automatic summary · not editorially reviewed
The key findings
PhenoAge was calculated from routine blood test results of patients attending a Geriatric Oncology clinic, and PhenoAgeAccel was the residual from a regression of PhenoAge against age. [1]
Data were available for 173 patients (62% male), and mean PhenoAge was higher than chronological age (84.3 vs 76.2). [1]
The abstract concludes that PhenoAgeAccel is a greater predictor of risk than chronological age in older people with cancer and calls it a promising biomarker for proposed stratification uses. [1]
The source at a glance
- Study type / format
- Abstract of a clinical data analysis (design not stated in the abstract).
- Population / context
- 173 patients attending a Geriatric Oncology clinic (62% male).
- Summary based on
- Study abstract
- Original publication
- August 14, 2026
Biological age from routine blood tests in cancer patients
The abstract describes cancer and ageing as linked in both directions: age is the strongest risk factor for cancer, and cancer and its treatments can accelerate ageing. Because biological age can differ from chronological age, the authors argue biomarkers are needed to stratify interventions aimed at minimising accelerated ageing. They calculated PhenoAge from routine blood test results of patients attending a Geriatric Oncology clinic. PhenoAgeAccel was defined as the residual from a regression of PhenoAge against age, i.e. how far measured biological age sits from the value expected for that age.
Supporting source [1]
Higher mean PhenoAge than age in 173 patients
Data were available for 173 patients, 62% of them male. Mean PhenoAge was higher than chronological age: 84.3 (12.6) versus 76.2 (7.24), with p reported as significant. The abstract concludes that PhenoAgeAccel is a greater predictor of risk than chronological age in older people with cancer. The authors call it a promising biomarker for stratifying patients for holistic geriatric assessment, dose reductions, or future geroprotective measures, potentially integrated into electronic healthcare record systems. These are proposed uses, not demonstrated benefits.
Supporting source [1]
Abstract-only scope of the PhenoAgeAccel analysis
Only the abstract was reviewed; the full text was not reviewed. The abstract reports a single clinic sample of 173 patients and does not state the study design, follow-up duration, which risk outcome was predicted, or effect sizes and confidence intervals for the comparison with chronological age. The p-value is truncated in the supplied text. The reported associations do not establish that PhenoAgeAccel causes outcomes, and the stratification and geroprotective uses remain proposals.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report study design, follow-up, the specific risk outcome, or effect sizes and confidence intervals, and the p-value is truncated. Associations are not causal, and the stratification and geroprotective uses are proposals.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bottomley C, Liuu E, Echarte Archanco B, Harari D, Kalsi T, de Pablo Gallega C, Welch C. · europepmc.org · August 14, 2026